BACKGROUND: There are limited data on individual human immunodeficiency virus (HIV) viral load (VL) trajectories at the population-level after the introduction of universal test and treat (UTT) in sub-Saharan Africa. METHODS: Human immunodeficiency virus VLs were assessed among HIV-positive participants through 3 population-based surveys in 4 Ugandan fishing communities surveyed between November 2011 and August 2017. The unit of analysis was a visit-pair (2 consecutive person-visits), which were categorized as exhibiting durable VL suppression, new/renewed VL suppression, viral rebound, or persistent viremia. Adjusted relative risks (adjRRs) and 95% confidence intervals (CIs) of persistent viremia were estimated using multivariate Poisson regression. RESULTS: There were 1346 HIV-positive participants (n = 1883 visit-pairs). The population-level prevalence of durable VL suppression increased from 29.7% to 67.9% during UTT rollout, viral rebound declined from 4.4% to 2.7%, and persistent viremia declined from 20.8% to 13.3%. Younger age (15-29 vs 40-49 years; adjRR = 1.80; 95% CI = 1.19-2.71), male sex (adjRR = 2.09, 95% CI = 1.47-2.95), never being married (vs currently married; adjRR = 1.88, 95% CI = 1.34-2.62), and recent migration to the community (vs long-term resident; adjRR = 1.91, 95% CI = 1.34-2.73) were factors associated with persistent viremia. CONCLUSIONS: Despite increases in durable VL suppression during roll out of UTT in hyperendemic communities, a substantial fraction of the population, whose risk profile tended to be younger, male, and mobile, remained persistently viremic.
BACKGROUND: There are limited data on individual human immunodeficiency virus (HIV) viral load (VL) trajectories at the population-level after the introduction of universal test and treat (UTT) in sub-Saharan Africa. METHODS: Human immunodeficiency virus VLs were assessed among HIV-positive participants through 3 population-based surveys in 4 Ugandan fishing communities surveyed between November 2011 and August 2017. The unit of analysis was a visit-pair (2 consecutive person-visits), which were categorized as exhibiting durable VL suppression, new/renewed VL suppression, viral rebound, or persistent viremia. Adjusted relative risks (adjRRs) and 95% confidence intervals (CIs) of persistent viremia were estimated using multivariate Poisson regression. RESULTS: There were 1346 HIV-positive participants (n = 1883 visit-pairs). The population-level prevalence of durable VL suppression increased from 29.7% to 67.9% during UTT rollout, viral rebound declined from 4.4% to 2.7%, and persistent viremia declined from 20.8% to 13.3%. Younger age (15-29 vs 40-49 years; adjRR = 1.80; 95% CI = 1.19-2.71), male sex (adjRR = 2.09, 95% CI = 1.47-2.95), never being married (vs currently married; adjRR = 1.88, 95% CI = 1.34-2.62), and recent migration to the community (vs long-term resident; adjRR = 1.91, 95% CI = 1.34-2.73) were factors associated with persistent viremia. CONCLUSIONS: Despite increases in durable VL suppression during roll out of UTT in hyperendemic communities, a substantial fraction of the population, whose risk profile tended to be younger, male, and mobile, remained persistently viremic.
Authors: Roos E Barth; Maarten F Schim van der Loeff; Rob Schuurman; Andy I M Hoepelman; Annemarie M J Wensing Journal: Lancet Infect Dis Date: 2010-03 Impact factor: 25.071
Authors: Awachana Jiamsakul; Azar Kariminia; Keri N Althoff; Carina Cesar; Claudia P Cortes; Mary-Ann Davies; Viet Chau Do; Brian Eley; John Gill; Nagalingeswaran Kumarasamy; Daisy Maria Machado; Richard Moore; Hans Prozesky; Elizabeth Zaniewski; Matthew Law Journal: J Acquir Immune Defic Syndr Date: 2017-11-01 Impact factor: 3.731
Authors: Joseph Kagaayi; Larry W Chang; Victor Ssempijja; M Kate Grabowski; Robert Ssekubugu; Gertrude Nakigozi; Godfrey Kigozi; David M Serwadda; Ronald H Gray; Fred Nalugoda; Nelson K Sewankambo; Lisa Nelson; Lisa A Mills; Donna Kabatesi; Stella Alamo; Caitlin E Kennedy; Aaron A R Tobian; John S Santelli; Anna Mia Ekström; Helena Nordenstedt; Thomas C Quinn; Maria J Wawer; Steven J Reynolds Journal: Lancet HIV Date: 2019-09-15 Impact factor: 12.767
Authors: Veena G Billioux; Mary K Grabowski; Joseph Ssekasanvu; Steven J Reynolds; Amanda Berman; Jeremiah Bazaale; Eshan U Patel; Eva Bugos; Anthony Ndyanabo; Alice Kisakye; Joseph Kagaayi; Ronald H Gray; Gertrude Nakigozi; Robert Ssekubugu; Fred Nalugoda; David Serwadda; Maria J Wawer; Larry W Chang Journal: AIDS Date: 2018-03-27 Impact factor: 4.177
Authors: Diane V Havlir; Laura B Balzer; Edwin D Charlebois; Tamara D Clark; Dalsone Kwarisiima; James Ayieko; Jane Kabami; Norton Sang; Teri Liegler; Gabriel Chamie; Carol S Camlin; Vivek Jain; Kevin Kadede; Mucunguzi Atukunda; Theodore Ruel; Starley B Shade; Emmanuel Ssemmondo; Dathan M Byonanebye; Florence Mwangwa; Asiphas Owaraganise; Winter Olilo; Douglas Black; Katherine Snyman; Rachel Burger; Monica Getahun; Jackson Achando; Benard Awuonda; Hellen Nakato; Joel Kironde; Samuel Okiror; Harsha Thirumurthy; Catherine Koss; Lillian Brown; Carina Marquez; Joshua Schwab; Geoff Lavoy; Albert Plenty; Erick Mugoma Wafula; Patrick Omanya; Yea-Hung Chen; James F Rooney; Melanie Bacon; Mark van der Laan; Craig R Cohen; Elizabeth Bukusi; Moses R Kamya; Maya Petersen Journal: N Engl J Med Date: 2019-07-18 Impact factor: 91.245
Authors: Mary K Grabowski; Steven J Reynolds; Joseph Kagaayi; Ronald H Gray; William Clarke; Larry W Chang; Gertrude Nakigozi; Oliver Laeyndecker; Andrew D Redd; Veena Billioux; Robert Ssekubugu; Fred Nalugoda; Maria J Wawer; David Serwadda; Thomas C Quinn; Aaron A R Tobian Journal: AIDS Date: 2018-01-28 Impact factor: 4.177
Authors: Veena G Billioux; Larry W Chang; Steven J Reynolds; Gertrude Nakigozi; Joseph Ssekasanvu; Mary K Grabowski; Robert Ssekubugu; Fred Nalugoda; Godfrey Kigozi; Joseph Kagaayi; David Serwadda; Ronald H Gray; Maria J Wawer Journal: J Int AIDS Soc Date: 2017-06-05 Impact factor: 5.396
Authors: Oluwasolape Olawore; Aaron A R Tobian; Joseph Kagaayi; Jeremiah M Bazaale; Betty Nantume; Grace Kigozi; Justine Nankinga; Fred Nalugoda; Gertrude Nakigozi; Godfrey Kigozi; Ronald H Gray; Maria J Wawer; Robert Ssekubugu; John S Santelli; Steven J Reynolds; Larry W Chang; David Serwadda; Mary K Grabowski Journal: Lancet HIV Date: 2018-02-25 Impact factor: 12.767
Authors: Ingrid T Katz; Annemarie E Ryu; Afiachukwu G Onuegbu; Christina Psaros; Sheri D Weiser; David R Bangsberg; Alexander C Tsai Journal: J Int AIDS Soc Date: 2013-11-13 Impact factor: 5.396
Authors: Geoffrey Ndikabona; John Bosco Alege; Nicholas Sebuliba Kirirabwa; Derrick Kimuli Journal: BMC Public Health Date: 2021-12-18 Impact factor: 3.295
Authors: Mark J Siedner; Mahomed-Yunus S Moosa; Suzanne McCluskey; Rebecca F Gilbert; Selvan Pillay; Isaac Aturinda; Kevin Ard; Winnie Muyindike; Nicholas Musinguzi; Godfrey Masette; Melendhran Pillay; Pravikrishnen Moodley; Jaysingh Brijkumar; Tamlyn Rautenberg; Gavin George; Rajesh T Gandhi; Brent A Johnson; Henry Sunpath; Mwebesa B Bwana; Vincent C Marconi Journal: Ann Intern Med Date: 2021-10-26 Impact factor: 51.598